-+ 0.00%
-+ 0.00%
-+ 0.00%

Optimi Health Advances Psilocybin, MDMA Clinical Programs; Phase 2b MDD Trial Dosing Set For Q1 2027

Benzinga·11/18/2026 12:34:16
Diffusion vocale

Proposed OPTI-101 protocol amendment converts the single-arm, open-label Phase 2 trial into a randomized, double-blind Phase 2b in severe major depressive disorder, enhancing statistical power; dosing expected Q1 2027 with topline data expected in 2028

Health Canada-cleared Phase 3 trial of OPTI-201 MDMA-assisted therapy in 100 veterans and front-line workers with PTSD expected to begin in 2027; Company plans to file a U.S. IND for OPTI-201 in addition to the proposed Canadian trial.

VANCOUVER, British Columbia, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ:OPTH, CSE:OPTI, FSE: 8BN))) (the "Company" or "Optimi"), a commercial-stage pharmaceutical drug developer and manufacturer of regulated psychedelic drug products, provides an update on its clinical programs, commercial supply, Ibogaine Initiative and a shares-for-debt settlement.

Highlights

OPTI-101: naturally derived psilocybin for major depressive disorder (MDD)

Phase 2b Trial: randomized, double-blind, active placebo-controlled trial in 200 adults with severe MDD; dosing expected to begin in Q1 2027; topline data expected in 2028.

U.S. FDA Pathway: preparing an IND for the FDA ahead of a planned U.S. Phase 3 trial for the same indication.

Natural Psilocybin Alternative: positioned as a naturally derived alternative to the synthetic psilocybin products advancing toward FDA approval.

OPTI-201: MDMA for post-traumatic stress disorder (PTSD)

Phase 3 Trial: Health Canada-cleared study in 100 veterans and front-line workers; initiation expected in 2027.

MDMA Market Opportunity: prescribed in Australia since October 2024; positioned to enter the U.S. if MDMA-assisted therapy is approved.

Potential U.S. FDA Pathway: IND filing with the FDA planned for 2027, alongside initiation of the Canadian Phase 3.

Ibogaine Initiative

Finished-dose capsules: first in-house production expected in the coming weeks, in various dosage strengths, for prospective ARPA-H-funded research.